News headlines about Viewray (NASDAQ:VRAY) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Viewray earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.2550093379706 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

Shares of Viewray (NASDAQ VRAY) opened at $8.38 on Thursday. Viewray has a 12-month low of $4.40 and a 12-month high of $10.64. The company has a debt-to-equity ratio of -1.67, a quick ratio of 1.20 and a current ratio of 1.59. The firm has a market capitalization of $644.30, a price-to-earnings ratio of -7.69 and a beta of 15.29.

A number of analysts have commented on the company. BidaskClub raised Viewray from a “sell” rating to a “hold” rating in a research report on Thursday, February 22nd. B. Riley assumed coverage on Viewray in a research note on Thursday, February 8th. They set a “buy” rating and a $13.50 price objective for the company. Mizuho restated a “buy” rating and issued a $12.00 price target on shares of Viewray in a research note on Tuesday, January 9th. Cantor Fitzgerald set a $13.00 price objective on Viewray and gave the stock a “buy” rating in a report on Monday, January 8th. Finally, ValuEngine cut Viewray from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $11.58.

ILLEGAL ACTIVITY WARNING: This story was first reported by Marea Informative and is the property of of Marea Informative. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.mareainformativa.com/2018/03/16/viewray-vray-receives-coverage-optimism-rating-of-0-03-updated-updated-updated.html.

Viewray Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Insider Buying and Selling by Quarter for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.